Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome—Comparison with other biomarkers

Kume, Noriaki; Mitsuoka, Hirokazu; Hayashida, Kazutaka; Tanaka, Masaru; Kominami, Goro; Kita, Toru

doi:10.1016/j.jjcc.2010.05.002

Cited by 58 publications

(54 citation statements)

References 36 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, a previous study has shown that sLOX-1 was able to detect ACS in cases in which TnT levels measured by a conventional assay were not increased during the acute stage, with similar sensitivity and specificity to the values determined for the whole population. 19 In the present study, in which the negative reference was non-ACS patients with similar chest symptoms and ECG abnormalities in the ER, we demonstrated, for the first time, that sLOX-1 was able to detect ACS during the acute stage in cases in which the hs-TnT levels were not increased, with similar sensitivity and specificity to those in the whole population.…”

Section: 15-18supporting

confidence: 60%

Soluble Lectin-Like Oxidized LDL Receptor-1 and High-Sensitivity Troponin T as Diagnostic Biomarkers for Acute Coronary Syndrome - Improved Values With Combination Usage in Emergency Rooms -

Kobayashi

Hata

Kume

et al. 2011

Circ J

Self Cite

View full text Add to dashboard Cite

Section: 15-18supporting

confidence: 60%

Soluble Lectin-Like Oxidized LDL Receptor-1 and High-Sensitivity Troponin T as Diagnostic Biomarkers for Acute Coronary Syndrome - Improved Values With Combination Usage in Emergency Rooms -

Kobayashi

Hata

Kume

et al. 2011

Circ J

Self Cite

View full text Add to dashboard Cite

“…The sLOX-1 levels have been shown to significantly increase in atherosclerotic plaque instability [23], diabetes mellitus [19], obesity [18], and are positively correlated with a reduction in body weight [24]. Association with coronary artery disease and metabolic disorders also suggested sLOX-1 as a biomarker for early detection of acute coronary syndrome [25,26]. We therefore sought to assess whether serum sLOX-1 levels could be used as an index of metabolic syndrome.…”

Section: Discussionmentioning

confidence: 99%

“…Level of sLOX-1 was a more specific and sensitive biomarker of ACS than others such as cardiac troponin T (cTnT), heart type-fatty acid binding protein, and high sensitive C-reactive protein [26,29]. The sLOX-1 was recommended as a suitable marker for early diagnosis of ACS than cTnT because 86% of the cTnT-negative patients showed sLOX-1 levels >1.0 ng/mL serum.…”

Section: Discussionmentioning

confidence: 99%

Soluble lectin-like oxidized low density lipoprotein receptor-1 in metabolic syndrome

2015

View full text Add to dashboard Cite

Background: Serum levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) reflect increases in LOX-1 receptor expression associated with inflammation and metabolic disorders. Objectives: To examine sLOX-1 levels in metabolic syndrome and association of sLOX-1 with classical risk factors, and with metabolic syndrome, a clustering of metabolic disorders associated with cardiovascular risk factors. Methods: We selected 148 serum samples from patient participants with metabolic syndrome and 206 samples from patients with non-metabolic syndrome as controls, using the modified National Cholesterol Educational Program Adult Treatment Panel III (NCEP-ATP III) criteria. Results: Levels of sLOX-1 were increased significantly in participants with metabolic syndrome (P < 0.001). Serum sLOX-1 was positively associated with body mass index (BMI), blood pressure, fasting plasma glucose, triglyceride, and total cholesterol, but negatively associated with high-density lipoprotein cholesterol. Analysis of serum sLOX-1 for metabolic syndrome showed 99.03% specificity and 100% sensitivity. The area under the receiver operating characteristic curve was 0.998 (95%CI 0.996-1.001, P < 0.001). A univariate analysis showed sLOX-1 was significantly correlated with metabolic syndrome, but was not after adjustment for sex, age, blood pressure, and BMI. Multivariate regression analysis found that being overweight (82.3; 95%CI 10.7−631.9), hyperglycemia (1.1; 95%CI 1.1−1.2), and hypertriglyceridemia (1.1; 95%CI 1.0−1.1) were significantly correlated with metabolic syndrome. HDL cholesterol was a protective factor (0.96; 95%CI: 0.93−0.99). Conclusions: Serum sLOX-1 is a suitable biomarker for diagnosis of metabolic syndrome. However, univariate and multivariate analysis suggested that sLOX-1 may be a modulating factor, and not an independent risk factor.

show abstract

“…LOX-1 is expressed on the cell surface and can be proteolytically cleaved at its extracellular domain and released as a soluble form (sLOX-1) ( 6 ). sLOX-1 level refl ects increased oxidative stress of vascular walls and has been identifi ed as a novel marker for early diagnosis of ACS ( 7,8 ). However, the exact mechanisms of sLOX-1 release from the cell membrane are poorly understood.…”

mentioning

confidence: 99%

CRP enhances soluble LOX-1 release from macrophages by activating TNF-α converting enzyme

Zhao

Zhang

Wang

et al. 2011

Journal of Lipid Research

View full text Add to dashboard Cite

An abundant increase in infl ammatory factors leads to acute infl ammatory diseases, such as acute coronary syndrome (ACS) ( 1 ). C-reactive protein (CRP), the prototypic marker of infl ammation, is one of the strongest predictors of cardiovascular events ( 2 ). Recent studies have demonstrated that CRP is present in atherosclerotic plaques and plays a pivotal role in promoting atherogenesis by regulating the expression and release of infl ammatory cytokines ( 3-5 ).Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), a type II membrane glycoprotein acting as a receptor for oxidized low-density lipoprotein, mediates vascular dysfunction ( 3 ). LOX-1 is expressed on the cell surface and can be proteolytically cleaved at its extracellular domain and released as a soluble form (sLOX-1) ( 6 ). sLOX-1 level refl ects increased oxidative stress of vascular walls and has been identifi ed as a novel marker for early diagnosis of ACS ( 7,8 ). However, the exact mechanisms of sLOX-1 release from the cell membrane are poorly understood.Tumor necrosis factor-a converting enzyme (TACE), a disintegrin and metalloproteinase, mediates the release of growth factors, receptors, and adhesion molecules ( 9 ). TACE is synthesized in a latent form and activated by reactive oxygen species (ROS) before reaching the cell membrane ( 10, 11 ). Studies report that CRP can upregulate ROS production by activating NAPDH Abstract Circulating levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) play an important role in the development and progression of atherosclerosis. We hypothesized that the infl ammatory marker C-reactive protein (CRP) might stimulate sLOX-1 release by activating tumor necrosis factor-␣ converting enzyme (TACE). Macrophages differentiated from THP-1 cells were stimulated with TNF-␣ and further treated with CRP in the absence or presence of specifi c inhibitors or small interfering RNA (siRNA). Our results showed that CRP increased sLOX-1 release from activated macrophages in a dosedependent manner and that these effects were regulated by China (No. 60831003), and the National Natural Science Foundation of China (Nos. 30700301, 30971096, 30972809, and 81000126 Abbreviations: ACS, acute coronary syndrome; Apo, apocynin; CRP, C-reactive protein; DCF-DA, 2 ′ ,7 ′ -dichlorodihydrofl uorescein diacetate; Fc g R, Fc gamma receptor; IL, interleukin; LOX-1, lectin-like oxidized low-density lipoprotein receptor-1; NAC, N-acetylcysteine; PBMC, peripheral blood mononuclear cell; PMSF, phenylmethyl sulfonylfl uoride; ROS, reactive oxygen species; siRNA, small interfering RNA; TACE, tumor necrosis factor-a converting enzyme; TAPI-1, tumor necrosis factor-a protease inhibitor 1; TNF-a , tumor necrosis factor-a . 1 X. Q. Zhao and M. W. Zhang contributed equally to this work.

show abstract

Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome—Comparison with other biomarkers

Abstract: Circulating sLOX-1 is a more sensitive and specific biomarker for ACS than TnT and H-FABP, and provides additional diagnostic values when measured in combination with TnT.

Cited by 58 publications

References 36 publications

Soluble Lectin-Like Oxidized LDL Receptor-1 and High-Sensitivity Troponin T as Diagnostic Biomarkers for Acute Coronary Syndrome - Improved Values With Combination Usage in Emergency Rooms -

Soluble Lectin-Like Oxidized LDL Receptor-1 and High-Sensitivity Troponin T as Diagnostic Biomarkers for Acute Coronary Syndrome - Improved Values With Combination Usage in Emergency Rooms -

Soluble lectin-like oxidized low density lipoprotein receptor-1 in metabolic syndrome

CRP enhances soluble LOX-1 release from macrophages by activating TNF-α converting enzyme

Contact Info

Product

Resources

About